TY  - JOUR
AU  - WANG, Yuhang
AU  - DI, Bin
AU  - YANG, Yong
AU  - JIANG, Cheng
PY  - 2026
TI  - Progress of innovative drug research in China
JO  - Journal of China Pharmaceutical University
SN  - 1000-5048
SP  - 275
EP  - 287
VL  - 57
IS  - 3
AB  - In recent years, China’s capacity for new drug research and development has been significantly strengthened, with major breakthroughs across multiple therapeutic areas, including cancer, autoimmune diseases, and metabolic disorders. An increasing number of domestically developed innovative drugs have been approved for marketing, gradually establishing a competitive position against imported drugs and expanding into global markets. This article systematically reviews the latest research progress of Class 1 innovative drugs in China from 2023 to 2024, categorizes representative approved drugs by therapeutic area, summarizes the clinical advantages and characteristics of representative drugs approved, analyzes in depth the current development trends of and challenges for China’s innovative pharmaceutical industry, and explores future directions, aiming to provide some reference for innovative drug research, industrial development, and policy-making in China.
UR  - https://doi.org/10.11665/j.issn.1000-5048.2026042802
DO  - 10.11665/j.issn.1000-5048.2026042802